Skip Navigation

Faculty Directory

Jean B. Nachega, MD

  • Associate Professor - Adjunct

Departmental Affiliations

Center & Institute Affiliations

Contact Information

410-502 6733

University of Pittsburgh Faculty Page

View Current Courses

Education

PhD, University of Cape Town, 2008
MPH, Johns Hopkins Bloomberg School of Public Health, 1999
MD, University of Louvain Medical School, 1989

Overview

Jean Nachega, MD, PhD, MPH, FRCP, DTM&H, is a tenured Associate Professor of Epidemiology, Infectious Diseases and Microbiology at University of Pittsburgh, USA; Adjunct Associate Professor of Epidemiology and International Health at Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; and Professor Extraordinary and Director of the Centre for Infectious Diseases at Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa. He has >25 years’ experience of research, teaching, and professional activities have included planning, design, implementing, and monitoring clinical trials, cohort studies and programs to improve HIV treatment cascade outcomes in sub-Saharan Africa.

He conducted a seminal study that showed that the relationship between adherence to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)-based HIV Therapy and virologic outcomes has linear dose-response pattern and is linked to various virologic outcomes. He was the first to quantify the savings in health care cost per month associated with excellent ART adherence, in a large South African HIV cohort. He has served as the Principal Investigator on several research and/or training grants, including some funded by US National Institutes of Health (NIH), US President Emergency Plan for AIDS Relief in Africa (PEPFAR), The European Developing Countries Clinical Trial Partnership (EDCTP), and The UK Wellcome Trust. He is Clinical Research Site (CRS) Lead Investigator for HIV studies in adults of the US NIH AIDS Clinical Trial Group (ACTG) Clinical Trial Unit (CTU) at Stellenbosch University. In addition, he is an ad hoc expert consultant for Bill and Melinda Gates Foundation; US Centers for Diseases Control & Preventions (CDC); and at World Health Organization (WHO), HIV Department, Geneva, within the HIV Treatment and Prevention Guidelines as well as HIV Drug Resistance Prevention Working Groups.

Honors and Awards

1) Member Elect, Delta Omega Public Health Honor Society , Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, May 2009; 2) John McGoldrick Senior Fellowship Award, Harvard School of Public Health, Boston, MA, USA, March 2009; 3) Member Elect, The Academy of Science of South Africa (ASSAF) 2008;4) Author (2nd) of a JAMA article nominated for the Lancet 2006 Article of the Year; 5) US National Institutes of Health/NIAID, Mentored-Patient Oriented Research Career Development Award (K23), March 2006; 6) Johns Hopkins Center for AIDS Research (CFAR) & National Institutes of Health (NIH), Pilot Grant Award, 2002; 7) Johns Hopkins University, School of Public Health Recognition Award, MPH Class of 1999; 8) Stelios M. Stelson Award, Johns Hopkins University, School of Public Health, MPH Class of 1999; 9) Dikembe Mutombo's African Education Award, Dikembe Mutombo Foundation, Atlanta, GA, 1998; 10) B.S. 1985, Magna Cum Laude & M.D. 1989, Cum Laude.

  • International Health
  • Epidemiology
  • HIV/AIDS
  • Tuberculosis
  • Global Health

Dr. Nachega has authored more than 150 peer-reviewed publications, including in top-tier journals such as The Lancet, JAMA, Annals of Internal Medicine, PlosMedicine and JIAS. He conducted a seminal study that showed that the relationship between adherence to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)-based HIV Therapy and virologic outcomes has linear dose-response pattern and is linked to various virologic outcomes. He was the first to quantify the savings in health care cost per month associated with excellent ART adherence, in a large South African HIV cohort. Selected publications below:

  • 1) Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007 Apr 17;146(8):564-73. PMID:17438315. (Impact Factor: 17.202; cited by over 100 PubMed Central articles)
  • 2) Nachega JB, Leisegang R, Bishai D, Nguyen H, Hislop M, Cleary S, Regensberg L, Maartens G. Association of antiretroviral therapy adherence and health care costs. Ann Intern Med. 2010 Jan 5;152(1):18-25. PMID:20048268 (Impact Factor: 17.202).
  • 3) Nachega JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M, Morroni C, Schoeman H, Knowlton AR, Maartens G.Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS. 2010 Jun 1;24(9):1273-80. PMID: 20453627 (Impact Factor: 5.54; cited by 39 PubMed Central articles)
  • 4) Nachega JB, Parienti JJ, Uthman OA, Gross R, Dowdy DW, Sax PE, Gallant JE, Mugavero MJ, Mills EJ, Giordano TP. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014 May;58(9):1297-307. PMID:24457345 (Impact Factor: 8.886; cited by 60 PubMed Central articles)
  • 5) Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, Mills EJ, Ho YS, Stringer JS, McIntyre JA, Mofenson LM. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS. 2012 Oct 23;26(16):2039-52. PMID:22951634 (Impact Factor: 17.202; cited by over 100 PubMed Central articles)
  • mHealth and cDOT to improve pMTCT outcomes in South Africa